plasmapheresis
plasmapheresis is a medical device with 31 clinical trials. Currently 2 active trials ongoing. Historical success rate of 76.2%.
Success Metrics
Based on 16 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
4
Mid Stage
6
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
61.5%
16 of 26 finished
38.5%
10 ended early
2
trials recruiting
31
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP 2 (PALADIN2)
Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP
Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
The Effect of Plasma Donation Frequency on Donor Health
PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
Clinical Trials (31)
Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP 2 (PALADIN2)
Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP
Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
The Effect of Plasma Donation Frequency on Donor Health
PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therapeutic Plasma Exchange (Plasmapheresis) in Participants With Duchenne Muscular Dystrophy (DMD) and Pre-existing Antibodies to AAVrh74
Treatment of Sickle Cell Anemia With Stem Cell Transplant
Plasmapheresis Versus Plasma Infusion from Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression
Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies
Effects of Plasmapheresis on Aging Biomarkers
Effect of Plasmapheresis on Clinical Improvement and Biological Parameters of Patients With Long-haul COVID
Plasmapheresis: a Multi-modal Approach
Predictors and Prognostic Factors of Gullian Barrie Syndrome Outcome
Study of Induction Therapy With Mitoxantrone and Plasmapheresis to Treat Aggressive Multiple Sclerosis
Quantitating the Impact of Plerixafor
The Efficacy of Plasmapheresis and Double Filtration Plasmapheresis (DFPP) in Kidney Transplant
High Volume Plasmapheresis for Refractory Hepatic Encephalopathy in Liver Intensive Care Unit.
Immunoadsorption vs. Plasmapheresis in the Escalation Therapy of Relapse in Multiple Sclerosis
Belimumab Impacting Transplant Eligibility
Intensive Insulin for Severe/Moderate Hypertriglyceridemia Pancreatitis.
Drug Details
- Intervention Type
- DEVICE
- Total Trials
- 31